Repositioning Candidate Details
| Candidate ID: | R0274 |
| Source ID: | DB00771 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Clidinium |
| Synonyms: | 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane; 3-hydroxy-1-methylquinuclidinium benzilate ester; N-methyl quinuclidinyl benzilate |
| Molecular Formula: | C22H26NO3 |
| SMILES: | C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. |
| CAS Number: | 7020-55-5 |
| Molecular Weight: | 352.4467 |
| DrugBank Indication: | For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. |
| DrugBank Pharmacology: | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. |
| DrugBank MoA: | Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors. |
| Targets: | Muscarinic acetylcholine receptor M1 antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|